EVENTS | VIEW CALENDAR
Avacta and Mologic begin diagnostic R&D collaboration
WETHERBY & CAMBRIDGE, U.K.—Avacta Group plc, developer of Affimer biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, announced in mid-June that they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point-of-care (POC) testing, using Avacta’s Affimer technology. As stated at the time of Avacta’s interim results recently, establishing commercial relationships in the POC testing market is one of the company’s key strategic objectives.
The non-exclusive collaboration with Mologic will focus on the development of novel Affimer-based diagnostic assays and the subsequent development of new lateral flow devices (LFDs) as POC diagnostics for human healthcare. Both companies will share in the future revenues from the commercialization of the marketed diagnostics.
The development of Affimer-based LFDs reportedly will address many of the existing limitations of traditional antibody-based systems. Current lateral flow technology relies predominantly on antibody-based detection which can limit specificity and the detection of certain classes of target molecule, the companies say—in addition, lengthy development times, combined with poor consistency and reproducibility, often create manufacturing challenges.
In comparison, they say, the generation of Affimer molecules typically takes weeks rather than months, and as the process is based on tuneable, recombinant technology, Affimer reagents can be specifically engineered to a wide range of targets, in a highly consistent, reproducible and cost-effective process.
Dr. Alastair Smith, CEO of Avacta, commented: “I am very pleased that we have established this collaborative partnership with Mologic, who are well-recognized as an innovative developer of lateral flow devices. It is important that Avacta forges co-development relationships such as this in the strategic application areas we have identified. They offer the opportunity to leverage each party’s expertise to rapidly progress and develop the Affimer technology in these key markets, for delivery of new and innovative tools for clinical and biotherapeutic applications. This partnership is a great endorsement of the value of Affimer technology in rapid test diagnostics, and I look forward to working together with Mologic and reporting on progress.”
“At Mologic we are continually working to find new ways to improve LFDs,” added Mark Davis, CEO of Mologic. “Partnering with Avacta and becoming one of the first companies to develop LFD tests using the Affimer platform, we have the potential to address a wider range of challenging targets than is possible with antibodies alone, with faster development times and improved performance, to the benefit of customers and patients.”